

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in





Anti-IL-20 [h15D2 (Fletikumab)] Standard Size Ab03711-10.3

This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.

This is a reformatted human IgG1 Fc Silent Fc Silent™ antibody, based on the original human IgG4 format, created for improved compatibility with existing reagents, assays and techniques.

Isotype and Format: Human IgG1, Fc Silent[™], Kappa

Clone Number: h15D2 (Fletikumab)

Alternative Name(s) of Target: IL20; Interleukin-20; ZCYTO10; Cytokine Zcyto10; NN-8226; NNC-0109-

0012

UniProt Accession Number of Target Protein: Q9NYY1

Published Application(s): inhibit, neutralize, therapeutic, WB, ELISA **Published Species Reactivity:** Human, Cynomolgus Monkey, Mouse

Immunogen: The original antibody was generated by immunizing mice by injecting subcutaneously 20 μ g of human IL-20 in FCA followed by two injections with 20 μ g of hIL20 in FIA.

Specificity: This antibody binds a linear epitope comprising amino acids 'YQTPDHYTLRKISSLANSFLTIK' of the human Interleukin-20. It also cross reacts with mouse and cynomolgus monkey IL-20 . IL-20 is a proinflammatory and angiogenic cytokine mainly secreted by monocytes, granulocytes, dendritic cells and skin keratinocytes that plays crucial roles in immune responses, regulation of inflammatory responses, hemopoiesis, as well as epidermal cell and keratinocyte differentiation. IL-20 shows effects in several inflammatory diseases, such as rheumatoid arthritis, atherosclerosis, cancer, and liver fibrosis via regulating cytokines and chemokines. IL-20 acts on renal cells and contributes to inflammation, fibrosis, and apoptosis through its receptors IL-20R1, IL-20R2, and IL-22R1.

Application Notes: This antibody can bind recombinant human IL-20 in an ELISA. This antibody was capable or neutralizing human IL20, cynomolgus IL20 and mouse IL20 induced proliferation of BaF-3(hIL20R) cells. This antibody can detect both native and denatured form of human IL-20 in a western blot. The original IgG4 version of this antibody, expressed in HEK293 cells, reacts with recombinant human IL-20 with a binding affinity of Kd= 32 pM (US8287861). It shows a very high potency in blocking IL-20 mediated activity on IL-20RA/IL-20RB and IL-22RA1/IL20R2 expressing cells with an IC50 value of 0.27 nM. It has a serum half-life of ~3 weeks in RA (Rheumatoid Arthritis) patients. Under the dose range from 0.05 to 3.0 mg/kg, Fletikumab was tolerable and non-toxic in patients with psoriasis. However, the clinical study was terminated because no apparent efficacy was observed. In the phase 2a trial, Fletikumab significantly

reduced tender joint counts and swollen joint counts in seropositive RA patients (PMID: 30319661).

Antibody First Published in: PMID:

Note on publication:

Product Form

Size: 100 µg Purified antibody.

Purification: Protein A affinity purified **Supplied In:** PBS with 0.02% Proclin 300.

Storage Recommendation: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -

20°C.

Concentration: 1 mg/ml.

Important note – This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.